The completion of data cleaning for Annovis Bio's Phase 2/3 study of Buntanetap is a significant milestone, indicating progress towards the final stages of the study. The anticipation of topline efficacy data, expected in April, is likely to generate investor optimism, contributing to a positive short-term impact on the company's stock price.